Financial results for the quarter ended on June 30, 2026

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001 Scrip Code 524506 ISIN INE683E01017 Series EQ Dear Sir/Madam, Subject Outcome of Board meeting held on August 14, 2026 Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other regulations if applicable, we hereby inform you that the Board of Directors of the Company at its meeting held today i.e. Friday, August 14, 2026, inter alia, considered and approved: 1. the standalone unaudited financial results for the quarter ended on June 30, 2026. 2. draft Directors’ Report, Secretarial Audit Report and other relevant annexures. 3. Forty fourth (44th) Annual General Meeting (“AGM”) will be held on Tuesday, September 29, 2026. The notice of AGM and Annual Report will be shared in due course of time. Book closure date will start from Wednesday, September 23, 2026 to Tuesday, September 29, 2026 (inclusive of both dates). M/s SARK & Associates LLP will act as scrutinizer for 44th AGM. Cut-off date shall be Tuesday, September 22, 2026. The meeting was started at 03:20 p.m. and concluded at 05:50 p.m. Kindly take the above on your record and disseminate the same for information of investors. Yours sincerely, For Coral Laboratories Limited Sushma Kadkade Director & CFO DIN 07791735 Place Mumbai Date August 14, 2026 Statement of Standalone Unaudited Financial Results for Quarter ended 30th June 2026 (Rs. in Lakhs ) (Except Figures in EPS) Sr. Particulars Quarter Ended Year Ended No (Refer Notes Below) 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unaudited) (Audited) (Unaudited) (Audited) 1 Income (a) Revenue from Operations 2962.31 2647.93 1882.14 8589.97 (b) Other Income 215.11 264.73 204.81 989.71 2 Total income 3177.42 2912.66 2086.96 9579.68 3 Expenses (a) Cost of Materials consumed 971.12 1129.86 833.30 3986.88 (b) Purchase of stock-in-trade 148.57 26.02 81.89 263.94 (c) Changes in inventories of finished goods, work-in- 246.53 (99.30) (41.46) (697.30) progress and stock-in-trade (d) Employee benefits expense 428.92 439.27 342.12 1591.53 (e) Depreciation and amortisation expense 66.42 54.17 45.32 213.66 (f) Financial Cost 3.12 1.01 5.79 17.14 (g)Other expenses 618.45 531.88 448.06 1923.59 Total Expenses 2483.12 2082.91 1715.03 7299.44 4 Profit from operations before exceptional items and tax 694.31 829.75 371.93 2280.24 5 Exceptional Items (Provision of Income tax of earlier year) 0.00 0.99 0.00 (31.25) 6 Profit from ordinary activities before tax 694.31 828.76 371.93 2311.49 7 Tax expense (a) Current Tax 155.00 214.00 115.00 578.00 (b) Deferred Tax 0.50 92.36 0.50 95.36 8 Profit from Continuing Operation 538.81 522.39 256.43 1638.13 9 Profit From discontinuing operations 10 Profit for the period 538.81 522.39 256.43 1638.13 11 Other Comprehensive Income A i) Items that will not be reclassified to profit and loss 396.53 (942.47) 563.15 (793.70) ii) Income tax relating to income that will not be reclassified - - - to profit and loss Total Comprensive income for the period (Comprising 12 profit and loss and other Comprehensive Income for the 935.33 (420.08) 819.58 844.43 period) Paid up Equity Share Capital (Face Value Rupees 10 per 13 357.26 357.26 357.26 357.26 share) Reserve excluding Revaluation reserve as per balance 14 0.00 0.00 0.00 20554.16 sheet of the previous accounting year 15 i)Earnings Per Share (before extraordinary items) (of Rs.10/- each): (a)Basic 15.08 14.62 7.18 45.85 (b)Diluted 15.08 14.62 7.18 45.85 ii)Earnings Per Share (after extraordinary items) (of Rs.10/- each) : (a)Basic 15.08 14.62 7.18 45.85 (b)Diluted 15.08 14.62 7.18 45.85 Coral Laboratories Limited Sushma Kadkade Mr. Girish Dhameja Director & CFO Whole Time Director DIN : 07791735 DIN : 07798455 Place : Mumbai Date : August 14, 2026 Notes: 1. The above Standalone Unaudited Financial Results were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on August 14, 2026 2. The Company has adopted Indian Accounting Standard and the above Financial Results have been prepared in accordance with Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Accounting Standard) Rules, 2015 and as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and guidelines issued by the Securities Exchange Board of India ("SEBI") as well as other accounting principles generally accepted in India. 3. The Company has only one segment viz. "Formulations" as per Indian Accounting Standard 108 of ICAI. 4. The Statutory Auditors have carried out the limited review of the financial results of the Company. 5. Previous period figures have been re-grouped / re-classified wherever necessary, to confirm to current periods classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective April 01, 2021. 6. Details of Investor Complaints for the Quarter: Beginning: Nil Received: Nil Disposed: Nil Pending: Nil Coral Laboratories Limited Sushma Kadkade Mr. Girish Dhameja Director & CFO Whole Time Director DIN : 07791735 DIN : 07798455 Place : Mumbai Date : August 14, 2026 Independent Auditor’s Review Report on Unaudited Quarterly Standalone Financial Results of the Company, pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The Board of Directors Coral Laboratories Limited 1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of CORAL LABORATORIES LIMITED (“the Company”), for the quarter ended June 30, 2026, (“the statement”) being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2. This Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the Indian Accounting Standard 34 “Interim Financial reporting” (“Ind AS 34”) as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 ‘Review of Interim Financial Information Performed by the Independent Auditor of the entity’ issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not able us to obtain assurance that we would become aware of all significant matters that be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. S C MEHRA & ASSOCIATES LLP, Chartered Accountants, Head Office : Office No. 42, 1st Floor, Singh Estate No. 3, Next to D’Mart, Near Mrinaltai Go [Showing first 8,000 characters — download PDF for full document]